Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How do you approach a breast cancer with noninflammatory skin invasion (T4b)?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

For a T4b breast cancer with limited skin involvement, BCT is an option. For adjuvant RT, I would consider bolus around the involved region for part of treatment. Bolus decision can be made based on final pathology and response to NACT (if treated with that approach). If the patient undergoes mastec...

When would you hold anticoagulation medications in patients undergoing a tandem and ovoid/ring?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We usually don’t hold unless planned for hybrid with needle placement. We would make sure sonogram is available for placement of tandem to avoid false track.

How would you approach residual ipsilateral diaphragmatic disease for M1a thymic cancer after induction chemotherapy and otherwise complete resection of primary and pleural disease?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

I would favor surgical approach to resect it if the patient can tolerate it. RT could be considered but motion management is crucial. The data on second-line chemo is very limited.

Would you consider SBRT for node negative small cell carcinoma of the prostate?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

There are no prospective data to guide the use of RT in the management of small cell carcinoma of the prostate. Retrospective data would suggest possible benefit at least in terms of control of disease in the prostate with the addition of local RT to systemic chemotherapy (see Oke et al., PMID 33824...

Would you offer upfront radiation for a large painful keloid of the chest that has arisen from an irritated pyoderma gangrenosum lesion? 

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Providence Health, St. Joseph Hospital

Radiation therapy is actually used (rarely) for pyoderma gangrenosum that has been unresponsive to medical management via immunosuppression [1]. Single fraction doses of 400 to 800 cGy have been used with slow regression of the lesions. In the case report cited, the lesion started fading after 3 mon...

Do you consider clinically node negative patients who have been on neoadjuvant endocrine therapy eligible for omission of axillary dissection if their sentinel node is positive?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

No good data and we have proceeded with regional nodal RT instead of ALND in these patients who are imaging negative and post endocrine SNLN node positive disease.

Would you offer RT for a nodal recurrence of NSCLC that has resolved radiographically after chemotherapy?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

Nodal recurrences are bad. When addressing nodal disease that "disappears" after chemotherapy, I have modeled my decision making on the premise used in small cell lung cancer treatment where even in the face of CRs on imaging after chemotherapy, radiotherapy was always added to the mediastinal (noda...

Is extramural venous invasion (EMVI) alone an indication to treat rectal cancer patients with total neoadjuvant therapy as opposed to neoadjuvant chemoradiation therapy or short course radiation therapy alone?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Ohio State University James Cancer Hospital and Solove Research Institute

EMVI detected on a staging pelvic MRI for rectal cancer has been shown to be a poor prognostic factor with an increased risk for distant metastases (Siddiqui et al., PMID 28449006). EMVI was also independently associated with a positive circumferential resection margin in low rectal tumors based on ...

What is the best way to approach adjuvant therapy for a FIGO Stage IIIB clear cell carcinoma of uterus s/p TAH BSO, with pathology showing extensive involvement of LUS, the cervix, and bilateral parametria with positive parametrial margins?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I wound get MRI imaging for pelvis to rule out gross disease and assuming staging is negative, would favor chemo RT to 50.4 Gy if not gross residual disease, followed by vaginal brachy boost and then additional chemo.

How would you manage a patient with PSA relapse 10 years after salvage radiotherapy with PSA doubling time<6 months?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Washington University School of Medicine

Depending on PSA, would image with PSMA PET - typically, will do around PSA 0.5 or higher (given most insurances will not cover multiple PETs in a short timespan, and detection rates of ~50% at PSA 0.5-1 per CONDOR). If no targetable (by XRT) disease on that, would discuss ADT given increased risk o...